4.7 Article

Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study

期刊

BRAIN
卷 143, 期 -, 页码 3589-3602

出版社

OXFORD UNIV PRESS
DOI: 10.1093/brain/awaa323

关键词

mitofusin-2; Charcot-Marie-Tooth disease type 2A; genotype-phenotype correlations; Charcot-Marie-Tooth Examination Score v2.0; standardized response mean

资金

  1. NIH
  2. Inherited Neuropathy Consortium (INC) [U54NS065712]
  3. BMA (Vera Down grant)
  4. National Institutes of Neurological Diseases and Stroke and office of Rare Diseases [U54NS065712]
  5. Muscular Dystrophy Association [MDA510281]
  6. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  7. MDA
  8. European Research Council [309548]
  9. Wellcome Investigator Award [109915/Z/15/Z]
  10. Medical Research Council (UK) [MR/N025431/1, 201064/Z/16/Z]
  11. Newton Fund (UK/Turkey) [MR/N027302/1]
  12. CMTA
  13. Wellcome Trust [109915/Z/15/Z] Funding Source: Wellcome Trust
  14. MRC [MR/N025431/2, G1000848, MR/N010035/1, MR/N025431/1] Funding Source: UKRI

向作者/读者索取更多资源

The study of 196 CMT2A patients (including dominant and recessive) found that childhood onset of autosomal dominant CMT2A is associated with more severe disease severity compared to adult onset, with significantly higher rates of using orthoses, wheelchairs, dexterity difficulties, and higher CMT Examination Score and CMT Neuropathy Score at initial assessment. Longitudinal data analysis showed significant increases in CMTESv2 and CMTESv2-R over 1-2 years, providing guidance for prognosis and clinical trial design.
Mitofusin-2 (MFN2) is one of two ubiquitously expressed homologous proteins in eukaryote cells, playing a critical role in mitochondrial fusion. Mutations in MFN2 (most commonly autosomal dominant) cause Charcot-Marie-Tooth disease type 2A (CMT2A), the commonest axonal form of CMT, with significant allelic heterogeneity. Previous, moderately-sized, cross sectional genotype-phenotype studies of CMT2A have described the phenotypic spectrum of the disease, but longitudinal natural history studies are lacking. In this large multicentre prospective cohort study of 196 patients with dominant and autosomal recessive CMT2A, we present an in-depth genotype-phenotype study of the baseline characteristics of patients with CMT2A and longitudinal data (1-2 years) to describe the natural history. A childhood onset of autosomal dominant CMT2A is the most predictive marker of significant disease severity and is independent of the disease duration. When compared to adult onset autosomal dominant CMT2A, it is associated with significantly higher rates of use of ankle-foot orthoses, full-time use of wheelchair, dexterity difficulties and also has significantly higher CMT Examination Score (CMTESv2) and CMT Neuropathy Score (CMTNSv2) at initial assessment. Analysis of longitudinal data using the CMTESv2 and its Rasch-weighted counterpart, CMTESv2-R, show that over 1 year, the CMTESv2 increases significantly in autosomal dominant CMT2A (mean change 0.84 +/- 2.42; two-tailed paired t-test P=0.039). Furthermore, over 2 years both the CMTESv2 (mean change 0.97 +/- 1.77; two-tailed paired t-test P=0.003) and the CMTESv2-R (mean change 1.21 +/- 2.52; two-tailed paired t-test P=0.009) increase significantly with respective standardized response means of 0.55 and 0.48. In the paediatric CMT2A population (autosomal dominant and autosomal recessive CMT2A grouped together), the CMT Pediatric Scale increases significantly both over 1 year (mean change 2.24 +/- 3.09; two-tailed paired t-test P=0.009) and over 2 years (mean change 4.00 +/- 3.79; two-tailed paired t-test P=0.031) with respective standardized response means of 0.72 and 1.06. This cross-sectional and longitudinal study of the largest CMT2A cohort reported to date provides guidance for variant interpretation, informs prognosis and also provides natural history data that will guide clinical trial design.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据